$BCDA
BioCardia, Inc.

2017 Q3 Form 10-Q Financial Statement

#000143774917018927 Filed on November 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $130.0K $117.0K
YoY Change 11.11% -2.5%
Cost Of Revenue $147.0K $196.0K
YoY Change -25.0%
Gross Profit -$17.00K -$79.00K
YoY Change -78.48%
Gross Profit Margin -13.08% -67.52%
Selling, General & Admin $1.322M $919.0K
YoY Change 43.85% 2197.5%
% of Gross Profit
Research & Development $1.700M $684.0K
YoY Change 148.54%
% of Gross Profit
Depreciation & Amortization $21.00K $9.000K
YoY Change 133.33%
% of Gross Profit
Operating Expenses $3.022M $1.603M
YoY Change 88.52% 3907.5%
Operating Profit -$3.039M -$1.682M
YoY Change 80.68%
Interest Expense $0.00 $520.0K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $38.00K -$1.572M
YoY Change -102.42%
Pretax Income -$3.000M $5.120M
YoY Change -158.59% 6300.0%
Income Tax $0.00
% Of Pretax Income 0.0%
Net Earnings -$3.001M -$3.254M
YoY Change -7.78% -4167.5%
Net Earnings / Revenue -2308.46% -2781.2%
Basic Earnings Per Share
Diluted Earnings Per Share -$707.5K $2.404M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $15.13M $19.44M
YoY Change -22.17% 41.59%
Cash & Equivalents $13.33M $552.0K
Short-Term Investments $1.800M
Other Short-Term Assets $190.0K $50.00K
YoY Change 280.0% 0.0%
Inventory $240.0K
Prepaid Expenses $188.0K
Receivables $90.00K
Other Receivables $0.00
Total Short-Term Assets $15.64M $19.48M
YoY Change -19.7% 41.36%
LONG-TERM ASSETS
Property, Plant & Equipment $163.0K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.00K
YoY Change
Total Long-Term Assets $217.0K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $15.64M $19.48M
Total Long-Term Assets $217.0K $0.00
Total Assets $15.86M $19.48M
YoY Change -18.58% 41.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $447.0K $330.0K
YoY Change 35.45%
Accrued Expenses $487.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.000M $330.0K
YoY Change 506.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $80.00K
YoY Change
Total Long-Term Liabilities $80.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.000M $330.0K
Total Long-Term Liabilities $80.00K $0.00
Total Liabilities $2.075M $330.0K
YoY Change 528.79%
SHAREHOLDERS EQUITY
Retained Earnings -$68.96M
YoY Change
Common Stock $38.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $13.79M $19.15M
YoY Change
Total Liabilities & Shareholders Equity $15.86M $19.48M
YoY Change -18.58% 41.36%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$3.001M -$3.254M
YoY Change -7.78% -4167.5%
Depreciation, Depletion And Amortization $21.00K $9.000K
YoY Change 133.33%
Cash From Operating Activities -$1.780M -$1.140M
YoY Change 56.14% -2950.0%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$10.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.780M -1.140M
Cash From Investing Activities -10.00K
Cash From Financing Activities 10.00K 0.000
Net Change In Cash -1.780M -1.140M
YoY Change 56.14% -2950.0%
FREE CASH FLOW
Cash From Operating Activities -$1.780M -$1.140M
Capital Expenditures -$10.00K
Free Cash Flow -$1.770M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Amendment Flag
AmendmentFlag
false
CY2017Q3 bcda Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
175000
CY2016Q4 bcda Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
CY2017Q3 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1393000
CY2016Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
848000
CY2017Q3 bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
CY2016Q3 bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
30000
bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
250000
CY2017Q3 bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
CY2016Q3 bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
-1085000
bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
-1224000
CY2017Q3 bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
CY2016Q3 bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
3000
bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
10000
CY2017Q3 bcda Collaboration Agreement Revenue
CollaborationAgreementRevenue
42000
CY2016Q3 bcda Collaboration Agreement Revenue
CollaborationAgreementRevenue
17000
bcda Collaboration Agreement Revenue
CollaborationAgreementRevenue
81000
bcda Collaboration Agreement Revenue
CollaborationAgreementRevenue
33000
CY2017Q3 bcda Grant Liability Current
GrantLiabilityCurrent
669000
CY2016Q4 bcda Grant Liability Current
GrantLiabilityCurrent
304000
CY2017Q3 bcda Holders Of Issued And Outstanding Shares Of Voting Stock Agreed With Reverse Stock Split Percent
HoldersOfIssuedAndOutstandingSharesOfVotingStockAgreedWithReverseStockSplitPercent
0.636
CY2017Q3 us-gaap Assets
Assets
15860000
CY2016Q4 us-gaap Assets
Assets
22082000
CY2017Q3 us-gaap Assets Current
AssetsCurrent
15643000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
21917000
CY2017Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1799000
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
447000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
525000
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
90000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
74000
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
487000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
478000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
828000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
771000
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
82711000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
80686000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
701000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
87000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1999000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
145000
CY2017Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
2000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4240688
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18637771
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2017Q3 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
CY2017Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1799000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
552000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13326000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3557000
us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8026000
us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3005000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38151548
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38131303
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38151548
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38131303
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
38000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
147000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
196000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
525000
us-gaap Cost Of Goods Sold
CostOfGoodsSold
578000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
3169000
CY2016Q3 us-gaap Costs And Expenses
CostsAndExpenses
1799000
us-gaap Costs And Expenses
CostsAndExpenses
9261000
us-gaap Costs And Expenses
CostsAndExpenses
4575000
CY2017Q3 us-gaap Customer Deposits Current
CustomerDepositsCurrent
62000
CY2016Q4 us-gaap Customer Deposits Current
CustomerDepositsCurrent
66000
CY2017Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
75000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
56000
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
160000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
71000
CY2017Q3 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2017Q3 us-gaap Depreciation
Depreciation
21000
CY2016Q3 us-gaap Depreciation
Depreciation
9000
us-gaap Depreciation
Depreciation
57000
us-gaap Depreciation
Depreciation
30000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
30000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.26
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-22000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
89000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
37000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
105000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-44000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-168000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-111000
CY2017Q3 us-gaap Interest Expense
InterestExpense
0
CY2016Q3 us-gaap Interest Expense
InterestExpense
520000
us-gaap Interest Expense
InterestExpense
0
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4700000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-80000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
505000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
16000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-45000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
545000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
235000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
19000
us-gaap Interest Expense
InterestExpense
1627000
CY2016Q3 us-gaap Other Operating Income
OtherOperatingIncome
us-gaap Other Operating Income
OtherOperatingIncome
58000
us-gaap Other Operating Income
OtherOperatingIncome
us-gaap Paid In Kind Interest
PaidInKindInterest
us-gaap Paid In Kind Interest
PaidInKindInterest
1627000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
107000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1799000
CY2017Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
79000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
76000
CY2017Q3 us-gaap Inventory Net
InventoryNet
240000
CY2016Q4 us-gaap Inventory Net
InventoryNet
135000
CY2017Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
74000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
59000
CY2017Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
87000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
CY2017Q3 us-gaap Inventory Write Down
InventoryWriteDown
15000
CY2016Q3 us-gaap Inventory Write Down
InventoryWriteDown
57000
us-gaap Inventory Write Down
InventoryWriteDown
25000
us-gaap Inventory Write Down
InventoryWriteDown
94000
CY2017Q3 us-gaap Liabilities
Liabilities
2075000
CY2016Q4 us-gaap Liabilities
Liabilities
1500000
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15860000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22082000
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2000000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1444000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1906000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6146000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3007000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3001000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3254000
us-gaap Net Income Loss
NetIncomeLoss
-8822000
us-gaap Net Income Loss
NetIncomeLoss
-6728000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
38000
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1572000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
60000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2592000
CY2017Q3 us-gaap Notes Payable
NotesPayable
0
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3039000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1682000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8882000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4136000
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2017Q3 us-gaap Other Operating Income
OtherOperatingIncome
35000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
298000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
406000
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
188000
CY2016Q3 us-gaap Revenues
Revenues
117000
us-gaap Revenues
Revenues
379000
us-gaap Revenues
Revenues
439000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
88000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
100000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
356000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
26000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
991000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
882000
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
163000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1700000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
684000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4028000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1622000
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68964000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60142000
CY2017Q3 us-gaap Revenues
Revenues
130000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
33948
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1322000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
919000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4708000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2375000
us-gaap Share Based Compensation
ShareBasedCompensation
1999000
us-gaap Share Based Compensation
ShareBasedCompensation
145000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
704946
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.44
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3491937
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4142692
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.78
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.90
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.08
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.48
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.34
CY2017Q3 us-gaap Short Term Investments
ShortTermInvestments
1799000
CY2016Q4 us-gaap Short Term Investments
ShortTermInvestments
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20243
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
13785000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
20582000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;">&nbsp;</td> <td style="width: 27pt;"> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(c)</div></div></div> </td> <td> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:Times New Roman, Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</div> <div style=" font-family: Times\ New\ Roman, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 63pt; text-align: justify; text-indent: 0pt;">The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment; allowances for doubtful accounts and sales returns; inventory valuation; fair value of the convertible preferred stock warrant liability; fair value of the maturity date preferred stock warrant liability; fair value of the convertible shareholder notes derivative liability; and share-based compensation.</div></div></div>
CY2017Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2016Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38146751
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1579852
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38141654
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1579264

Files In Submission

Name View Source Status
0001437749-17-018927-index-headers.html Edgar Link pending
0001437749-17-018927-index.html Edgar Link pending
0001437749-17-018927.txt Edgar Link pending
0001437749-17-018927-xbrl.zip Edgar Link pending
bcda-20170930.xml Edgar Link completed
bcda-20170930.xsd Edgar Link pending
bcda-20170930_cal.xml Edgar Link unprocessable
bcda-20170930_def.xml Edgar Link unprocessable
bcda-20170930_lab.xml Edgar Link unprocessable
bcda-20170930_pre.xml Edgar Link unprocessable
bcda20170930_10q.htm Edgar Link pending
ex_99167.htm Edgar Link pending
ex_99168.htm Edgar Link pending
ex_99169.htm Edgar Link pending
ex_99170.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending